2023 Chemotherapy Shortages Drove Altered Treatment Plans, Persistent Cost Increases
The 2023 cisplatin shortage led to shifts toward the use of alternative agents for use in head and neck cancer, as well as increased drug costs.| OncLive
The 2023 cisplatin shortage led to shifts toward the use of alternative agents for use in head and neck cancer, as well as increased drug costs.| OncLive
OncLive announces the inductees of the 13th annual Giants of Cancer Care recognition program.| OncLive
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.| OncLive
Coy Heldermon, MD, PhD, discusses a phase 1/2 trial design evaluating pharmacokinetics and safety of epidiferphane given with taxane chemotherapy in breast cancer.| OncLive
